• Users Online: 348
  • Print this page
  • Email this page
CASE REPORT
Year : 2022  |  Volume : 2  |  Issue : 4  |  Page : 911-912

Tofacitinib in juvenile idiopathic arthritis-associated uveitis


1 Department of Uvea and Ocular Inflammation, Prabha Eye Clinic and Research Centre and Vittala International Institute of Ophthalmology, Bengaluru, Karnataka, India
2 Department of Pediatric Rheumatology, Manipal Hospitals, Indira Gandhi Institute of Child Health, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Kalpana Babu
504, 40th Cross, Jayanagar 8th Block, Bengaluru – 560 070, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_789_22

Rights and Permissions

Tofacitinib, a Jannus kinase inhibitor, is used in the treatment of rheumatoid arthritis and recently has been used to treat polyarticular juvenile idiopathic arthritis (JIA). In this case report, we report the resolution of refractory anterior uveitis (OS) in a 5-year-old girl with polyarticular JIA. She had failed conventional immuno-modulation (methotrexate, mycophenolate mofetil, and oral steroids). As she could not afford adalimumab, tofacinitib was added, resulting in resolution of anterior uveitis. During the last follow-up (after 8 months), her best corrected visual acuity is 6/9 (OD) and 6/12 (OS). Tofacitinib may be considered as a cost-effective option for refractory JIA-associated uveitis in the developing world.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed284    
    Printed6    
    Emailed0    
    PDF Downloaded30    
    Comments [Add]    

Recommend this journal